{"organizations": [], "uuid": "aa63b33608196b2e4967cf49f5e65beb242c2bef", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biohaven-pharma-says-safety-profil/brief-biohaven-pharma-says-safety-profile-thus-far-favours-rimegepant-in-comparison-with-allergans-ubrogepant-idUSFWN1R80OV", "country": "US", "domain_rank": 408, "title": "BRIEF-Biohaven Pharma Says Safety Profile Thus Far Favours Rimegepant, In Comparison With Allergan's Ubrogepant", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.285, "site_type": "news", "published": "2018-03-26T21:36:00.000+03:00", "replies_count": 0, "uuid": "aa63b33608196b2e4967cf49f5e65beb242c2bef"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biohaven-pharma-says-safety-profil/brief-biohaven-pharma-says-safety-profile-thus-far-favours-rimegepant-in-comparison-with-allergans-ubrogepant-idUSFWN1R80OV", "ord_in_thread": 0, "title": "BRIEF-Biohaven Pharma Says Safety Profile Thus Far Favours Rimegepant, In Comparison With Allergan's Ubrogepant", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "allergan", "sentiment": "negative"}, {"name": "brief-biohaven pharma says safety profile thus far favours rimegepant", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Allergan Plc:\n* BIOHAVEN PHARMACEUTICAL SAYS IN TERMS OF COMPARISON OF RIMEGEPANT WITH ALLERGAN’S UBROGEPANT, THE SAFETY PROFILE THUS FAR FAVOURS RIMEGEPANT - CONF CALL\n* BIOHAVEN PHARMACEUTICAL SAYS “WE’RE GONNA HAVE A LOT OF OPTIONALITY WITH REGARD TO HOW WE COMMERCIALIZE” RIMEGEPANT - CONF CALL Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T21:36:00.000+03:00", "crawled": "2018-03-27T11:40:42.000+03:00", "highlightTitle": ""}